D
Live / Applied — Third extension granted (statement of use) (as of 04 Dec 2025)
What this means for you
Not registered yet, but its 03 Mar 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97821995
- Mark type
- Design + words
- Filed
- 03 Mar 2023
- Published for opposition
- 09 Apr 2024
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 001 — Chemicals: Reagents for research use; Reagents for research purposes of drug discovery and development; Reagents for clinical use in the nature of diagnostic reagents for clinical and medical laboratory use
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and therapeutic agents for use in the treatment and prevention of neurodegenerative diseases, cancer, metabolic disease, auto-immune diseases, inflammation, infectious disease, prion-based diseases, cardiovascular diseases, women's health in the nature of uterine fibroids and Polycystic Ovary Syndrome (PCOS), renal disease, pulmonary diseases, neurological disease, fibrosis, liver diseases and wound healing; Reagents for medical use; Reagents for clinical use in the nature of clinical medical use
- Class 009 — Scientific and electric apparatus: Downloadable computer software using artificial intelligence for software development, machine learning, integrated databases and workflow processes in the fields of scientific research and drug discovery
- Class 042 — Scientific and technological services: Scientific research in the field of genetics, gene therapy and genetic engineering; genetic testing for scientific research purposes; Scientific, biological, pharmaceutical and medical research services; Laboratory research in the fields of genetics, drug development, biotechnology, microbiology and molecular biology; Pharmaceutical drug discovery and drug development services; Biological research and development services; Scientific condensate-based research in the field of drug discovery and drug development; Providing temporary use of online, non-downloadable computer software using artificial intelligence for machine learning, integrated databases and workflow processes for use in the fields of scientific research and drug discovery
Owner
- Dewpoint Therapeutics, Inc., Boston, MA, US
- Dewpoint Therapeutics, Inc., Boston, MA, US
Prosecution history
- 05 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Dec 2025 — SOU EXTENSION 3 GRANTED
- 04 Dec 2025 — SOU EXTENSION 3 FILED
- 04 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Jun 2025 — SOU EXTENSION 2 GRANTED
- 03 Jun 2025 — SOU EXTENSION 2 FILED
- 03 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Dec 2024 — SOU EXTENSION 1 GRANTED
- 02 Dec 2024 — SOU EXTENSION 1 FILED
- 02 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 04 Jun 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 09 Apr 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 09 Apr 2024 — PUBLISHED FOR OPPOSITION